MetaCap

Alkermes plc Company Profile

NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

44.94-1.24 (-2.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Alkermes at a glance

Alkermes plc (NASDAQ: ALKS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Dublin, Ireland. Alkermes is led by Mr. Blair C. Jackson and employs about 2,050 people. The company's shares have traded publicly since 1991.

At a market capitalization of $7.55 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001520262, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Alkermes do?

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Business description based on the company's public filings.

Company information

Legal name
Alkermes plc
Ticker
NASDAQ: ALKS
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Blair C. Jackson
Employees
2,050
Headquarters
Connaught House, Dublin, Ireland
Phone
353 1 772 8000
IPO year
1991
SEC CIK
0001520262

Companies similar to Alkermes

ALKS peer companies
CompanyPrice% ChgMarket capCompare
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs ALKS
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs ALKS
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs ALKS
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs ALKS
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs ALKS
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs ALKS
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs ALKS
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs ALKS

Related